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ABSTRACT Nonmenstrual toxic shock syndrome (nmTSS), linked to TSST-1-producing
CC30 Staphylococcus aureus, is the leading manifestation of toxic shock syndrome
(TSS). Due to case rarity and a lack of tractable animal models, TSS pathogenesis is
poorly understood. We developed an S. aureus abscess model in HLA class II trans-
genic mice to investigate pathogenesis and treatment. TSST-1 sensitivity was estab-
lished using murine spleen cell proliferation assays and cytokine assays following
TSST-1 injection in vivo. HLA-DQ8 mice were infected subcutaneously with a tst-
positive CC30 methicillin-sensitive S. aureus clinical TSS-associated isolate. Mice re-
ceived intraperitoneal ﬂucloxacillin, clindamycin, ﬂucloxacillin and clindamycin, or a
control reagent. Abscess size, bacterial counts, TSST-1 expression, and TSST-1 bioac-
tivity were measured in tissues. Antibiotic effects were compared with the effects of
control reagent. Puriﬁed TSST-1 expanded HLA-DQ8 T-cell V subsets 3 and 13 in
vitro and instigated cytokine release in vivo, conﬁrming TSST-1 sensitivity. TSST-1
was detected in abscesses (0 to 8.0 g/ml) and draining lymph nodes (0 to 0.2 g/
ml) of infected mice. Interleukin 6 (IL-6), gamma interferon (IFN-), KC (CXCL1), and
MCP-1 were consistent markers of inﬂammation during infection. Clindamycin-
containing antibiotic regimens reduced abscess size and TSST-1 production. Infection
led to detectable TSST-1 in soft tissues, and TSST-1 was detected in draining lymph
nodes, events which may be pivotal to TSS pathogenesis. The reduction in TSST-1
production and lesion size after a single dose of clindamycin underscores a potential
role for adjunctive clindamycin at the start of treatment of patients suspected of
having TSS to alter disease progression.
IMPORTANCE Staphylococcal toxic shock syndrome (TSS) is a life-threatening illness
causing fever, rash, and shock, attributed to toxins produced by the bacterium
Staphylococcus aureus, mainly toxic shock syndrome toxin 1 (TSST-1). TSS was in the
past commonly linked with menstruation and high-absorbency tampons; now, TSS is
more frequently triggered by other staphylococcal infections, particularly of skin and
soft tissue. Investigating the progress and treatment of TSS in patients is challeng-
ing, as TSS is rare; animal models do not mimic TSS adequately, as toxins interact
best with human immune cells. We developed a new model of staphylococcal soft
tissue infection in mice producing human immune cell proteins, rendering them
TSST-1 sensitive, to investigate TSS. The signiﬁcance of our research was that TSST-1
was found in soft tissues and immune organs of mice and that early treatment of
mice with the antibiotic clindamycin altered TSST-1 production. Therefore, the early
treatment of patients suspected of having TSS with clindamycin may inﬂuence their
response to treatment.
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Staphylococcal toxic shock syndrome (TSS) is a potentially lethal illness characterizedby fever, rash, desquamation, organ dysfunction, and shock. The syndrome is
attributed to superantigens produced by Staphylococcus aureus, in particular, toxic
shock syndrome toxin 1 (TSST-1). TSST-1 has been associated with almost all menstrual
TSS (mTSS) and half of nonmenstrual TSS (nmTSS) cases (1), while staphylococcal
enterotoxins A, B, and C (SEA, SEB, and SEC) are implicated in the remaining nmTSS
cases (2, 3). Superantigens bind simultaneously to the HLA class II molecule on
antigen-presenting cells and the T-cell receptor, causing massive T-cell activation,
expansion, and cytokine release (2). In the United Kingdom, nmTSS is now more
common than mTSS. Skin and soft tissue infections (SSTI) are the most frequent trigger
for nmTSS, which, in the United Kingdom, is associated with TSST-1-producing strains
in 41% of cases (4). Due to its rarity, TSS pathogenesis is poorly understood, and there
is a paucity of clinical data to guide treatment choices. Notwithstanding a lack of clinical
trial or in vivo data, combination antimicrobial treatment with -lactams and protein
synthesis inhibitors is recommended for staphylococcal TSS (5), based solely upon in
vitro studies and extrapolation from observational studies of streptococcal TSS.
Murine models of TSS may provide insight into TSS pathogenesis and antimicrobial
efﬁcacy but are hampered by low-afﬁnity interactions between murine major histo-
compatibility class II (MHC II) and staphylococcal superantigens. Prior sensitization with
lipopolysaccharide (6) or D-galactosamine (7) has been used to induce superantigen-
mediated lethality, though the pathological changes incurred may differ markedly from
those induced by superantigen alone. Transgenic expression of human HLA class II can
render mice superantigen sensitive and allows investigation of superantigen-associated
inﬂammation without the need for sensitization (8), removing potential experimental
confounders. There are few recent studies of staphylococcal TSS infection using con-
temporary clinical strains and none that evaluate disease progression and toxin release
in superantigen-sensitive mice. We developed a humanized transgenic model of
superantigen-associated SSTI using a clinical TSST-1-producing CC30 methicillin-
sensitive S. aureus (MSSA) TSS-associated isolate to investigate the pathogenesis and
treatment of nmTSS.
(This work was presented in part at the 55th Interscience Conference on Antimi-
crobial Agents and Chemotherapy [ICAAC], San Diego, CA, in September 2015.)
RESULTS
HLA-DQ8 transgenic mice are superantigen and TSST-1 sensitive. The prolifer-
ation of mouse spleen cells in response to superantigens was assessed to determine the
superantigen sensitivity of transgenic mice in comparison to that in wild-type mice to
recapitulate human immune responses to superantigens, such as those which occur in
TSS. Spleen cells of HLA-DQ8 transgenic mice were markedly more sensitive to puriﬁed
TSST-1 than spleen cells from wild-type C57BL/6 mice (Fig. 1A). Indeed, HLA-DQ8 spleen
cells were more sensitive to all staphylococcal superantigens tested than cells from
either HLA-DR4 or wild-type mice (see Fig. S2 in the supplemental material). Because of
this, all further experiments were performed using HLA-DQ8 mice.
The response of HLA-DQ8 splenocytes to superantigens was compared to that of
human peripheral blood mononuclear cells (PBMCs). HLA-DQ8 mice were sensitive to
TSST-1 at micromolar concentrations and to SEB at nanomolar concentrations. Human
PBMCs were sensitive at picomolar concentrations to both superantigens (Fig. S3).
Following coculture, TSST-1 expanded HLA-DQ8 mouse spleen cell T-cell receptor
(TCR) V subsets TCR V3 and TCR V13 (Fig. 1B). HLA-DQ8 mice treated with TSST-1
intraperitoneally (i.p.) had elevated levels of the serum cytokines interleukin 6 (IL-6), KC
(CXCL1), IL-12p70, IL-17, and MCP-1 at 2 h and gamma interferon (IFN-) at 6 h
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FIG 1 HLA-DQ8mice are superantigen sensitive. (A) Sensitivities of HLA-DQ8 and C57BL/6 splenocytes to TSST-1. Splenocytes (1 106/ml) from
HLA-DQ8 and C57BL/6 mice were exposed to 0 to 10g/ml of TSST-1. Proliferation was measured by [3H]thymidine uptake. CPM, counts per
minute. Proliferation in the presence of 5g/ml concanavalin (positive control) was 229,806 48,570 CPM for C57BL/6 spleen cells and
373,349  56,008 CPM for HLA-DQ8 spleen cells. Data are means  SD of results from three individual mice. *, P  0.05; **, P  0.01
between HLA-DQ8 and C57BL/6 by ANOVA. (B) Percentages of spleen cells from HLA-DQ8 mice in each CD3 TCR V subset
expanded by TSST-1. Spleen cells (1  106/ml) were labeled with CellTrace far-red proliferation dye (CTFR) and stimulated with
2.5 g/ml TSST-1, 2.5 g/ml concanavalin A (positive control), or left unstimulated (negative control). Bars show means  SD of
results for 3 mice. ****, P  0.0001 between TSST-1 and unstimulated splenocytes by two-way ANOVA. (C) Serum cytokines 2 h and
6 h after i.p. injection of 80 g TSST-1 in HLA-DQ8 or C57BL/6 mice. Values to the right of the dashed line refer to the y axis on the
right. Medians and 5th, 25th, 50th, 75th, and 95th centiles for ﬁve individual mice are shown. *, P  0.05 by Mann-Whitney U test
between HLA-DQ8 and C57BL/6 mice treated with TSST-1. IFN, gamma interferon; IL-6, interleukin 6; IL12p70, interleukin 12 (p70);
IL-17, interleukin 17; KC, CXCL1; MCP-1, monocyte chemotactic protein 1.
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compared to levels in wild-type C57BL/6 control mice (Fig. 1C). Levels of other cyto-
kines tested did not differ between groups (Table S2).
Modeling soft tissue infection in HLA-DQ8 mice. Having demonstrated respon-
siveness to TSST-1, HLA-DQ8 transgenic mice were infected subcutaneously (s.c.) with
TSST-1-producing S. aureus, and groups were euthanized at 24, 48, and 72 h. By 24 h,
there was visible abscess formation at the inoculation site. Abscess volume and
bacterial load decreased by 72 h. Bacteria disseminated to the spleen at all time points
in 17/18 mice, though spleen bacterial loads decreased during infection. Two to three
mice in each group had detectable bacteremia at each time point (Fig. 2). Weight loss
was maximal 24 h following infection (median, 9.3%; range, 0 to 15.9%).
tst mRNA transcripts in pus obtained from the abscess were detectable in 5/6 mice
at 24 h, 1/6 mice at 48 h, and 2/6 mice at 72 h and were maximal at 24 h (Fig. 3A). Due
to the use of abscess samples for RNA and other analyses, measurement of TSST-1
protein was undertaken for just one mouse at each time point; TSST-1 protein was,
however, detected by Western blotting in the 24-h pus sample (8 g/ml) but not at 48
or 72 h. Human PBMCs were sensitive to TSST-1 at nanomolar concentrations (Fig. 3B).
Pus recovered from abscesses demonstrated sustained mitogenic activity toward hu-
man PBMCs at 24 and 48 h, but not at 72 h, when diluted 1:100. Strong mitogenic
activity toward human PBMCs was also detected in all sera at 24 h despite infrequent
bacteremia, consistent with the presence of superantigen in the mouse serum (Fig. 3C
and D).
Serum cytokines and chemokines were maximal 24 h postinfection, consistent with
the ﬁndings of puriﬁed TSST-1 challenge. IL-6, IFN-, KC, MCP-1, MIP-1, and granulo-
FIG 2 Bacteriology of TSST-1-producing S. aureus infection in HLA-DQ8 mice. Mice were infected subcutaneously with
tst-positive CC30 MSSA strain HSS357 (1  109 CFU). At 24, 48, and 72 h, mice were culled and abscess dimensions were
measured (A), pus was extracted and plated for CFU quantiﬁcation (B), spleens were extracted, homogenized, and
plated for CFU counting (C), and blood cultures were taken by cardiac puncture (D). Median values are shown from six
HLA-DQ8 mice per group. *, P  0.05; **, P  0.01 by Mann-Whitney U test of HLA-DQ8 groups compared between 24
h and 72 h.
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cyte colony-stimulating factor (G-CSF) were raised in infected transgenic mice, unlike
with control HLA-DQ8 mice inoculated with phosphate-buffered saline (PBS) alone
(Table S3).
On histological analysis of abscess sections from single mice, bacteria were detected
on each day of infection, accompanied by heavy subcutaneous inﬁltration by neutro-
phils, with inﬂammation (Fig. S4).
Draining lymph node involvement during S. aureus infection. To determine
whether S. aureus infection involved draining inguinal lymph nodes, four HLA-DQ8
mice infected with the CC30 tst-positive S. aureus strain HSS357 were euthanized 24 h
following infection and dissected, with careful removal of inguinal lymph nodes.
Bacteria were detected in the subcutaneous abscess (median, 1.3  107 CFU; range,
0 to 2.8  107 CFU/abscess), the ipsilateral inguinal lymph node (median, 8.5 CFU;
range, 0 to 1.4  104 CFU/lymph node), and spleen (median, 4.0  101 CFU; range,
2.0  101 to 2.6  103 CFU/mg spleen), but not the contralateral inguinal lymph node
or blood. The greatest bacterial burden was in the subcutaneous abscess, but there was
also abscessation in the ipsilateral inguinal lymph nodes of all mice. TSST-1 was
detected at the highest level in pus from the subcutaneous abscesses of all four mice
and was detected in the ipsilateral inguinal lymph nodes from 2/4 mice but not in any
contralateral inguinal lymph node (Fig. 4A). Mitogenicity was elicited (in descending
order of magnitude) from the subcutaneous abscess pus, ipsilateral inguinal lymph
FIG 3 Local tst transcription and mitogenicity of pus and serum in TSST-1-producing S. aureus infection in HLA-DQ8 mice. Groups
of 6 mice were infected subcutaneously with tst-positive S. aureus strain HSS357 (1  109 CFU). At 24, 48, and 72 h, groups were culled
and abscess pus was extracted. (A) Copies of tst transcripts were measured by quantitative real-time PCR per 10,000 copies of rrsA.
(B) Proliferation of human PBMCs incubated with 0 to 1 g/ml TSST-1 in triplicate, measured by BrdU uptake. Human PBMCs were
incubated with pus (C) and serum (D) obtained at 24-h time points after infection. Proliferation was measured by BrdU uptake. Data
and medians are shown for 6 individual HLA-DQ8 mice per group. Negative, tissue culture medium (RPMI 1640) alone. *, P  0.05;
**, P  0.01 by Mann-Whitney U test of HLA-DQ8 groups compared to one another on each day of infection.
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node, and serum from infected mice (Fig. 4B), consistent with the presence of supe-
rantigen.
Antibiotic impact on lesion size and superantigen toxin production. S. aureus-
infected HLA-DQ8 mice were treated with a single dose of ﬂucloxacillin (FCX), clinda-
mycin (CLD), FCX-CLD, or sterile PBS at 24 h postinfection and were euthanized at 30
h, i.e., 6 h after antibiotic or PBS administration, to assess the impact of antibiotics on
TSST-1 production and the host immune response. Within 6 h of antibiotic adminis-
tration, mice treated with CLD-containing regimens had smaller abscesses and reduced
local TSST-1 production compared to those of mice treated with PBS or FCX alone
(Fig. 5A and B). Accordingly, there was a clear reduction in pus and serum sample
mitogenicity (Fig. 5C and D). The pus sample was not subjected to quantitative
real-time PCR (qRT-PCR) of tst transcripts due to previously low levels of transcript
detection.
Cytokine differences between control and antibiotic-treated groups were negligible;
however, the level of IL-2 was reduced in mice treated with CLD-containing regimens
compared to those in mice treated with PBS or FCX, consistent with reduced T-cell
stimulation (Fig. 6). The single antibiotic dose did not impact the numbers of CFU
detected in the abscess, lymphoid organs, or blood compared with those detected in
mice given PBS (Fig. 7). In particular, CLD did not confer any additional beneﬁt with
regard to bacteriological clearance during this short treatment time.
DISCUSSION
We describe an S. aureus subcutaneous-abscess model in HLA-DQ8 transgenic mice.
These mice demonstrated sensitivity to TSST-1, which expanded the murine T-cell
receptor V subsets TCR V3 and TCR V13. S. aureus disseminated to the draining
inguinal lymph nodes and spleen, while TSST-1 production was detected in not only
the subcutaneous abscess but also the draining inguinal lymph node, signaled by
mitogenic activity in the abscess pus, the ipsilateral inguinal lymph node, and serum.
Clindamycin-containing antibiotic regimens reduced abscess volume, TSST-1 produc-
tion, and the overall mitogenic activity of the lesion within just 6 h of a single
treatment.
Experimental comparison of infections with different strains of transgenic mice was
not possible in this study. It was notable that HLA-DQ8 mice appeared to be more
sensitive to TSST-1 than HLA-DR4 mice in vitro, despite previous work indicating that
TSST-1 binds to HLA-DR molecules with levels of afﬁnity greater than (9) or equal to (10)
its levels of afﬁnity to HLA-DQ molecules. Polymorphisms in HLA-DR are also known to
FIG 4 Tissue TSST-1 production and mitogenicity during infection with TSST-1-producing S. aureus in
HLA-DQ8 mice. HLA-DQ8 mice were infected subcutaneously with tst-positive CC30 MSSA strain HSS357
(1  109 CFU). (A) Mice were culled at 24 h after infection, and TSST-1 protein present in the abscess and
inguinal lymph nodes (ILN) was measured by Western blotting. TSST-1 protein of known concentration
was measured to quantify the amount of TSST-1 by densitometry. (B) Human PBMC responses to pus,
inguinal lymph nodes, and sera from infected mice. Proliferation was measured by BrdU uptake.
Negative, tissue culture medium (RPMI 1640) alone. ND, not detected. *, P  0.05.
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affect transgenic-mouse responses to TSST-1 (11). It is likely that differential expression
of the HLA transgenes and endogenous H2 or responding T-cell subset repertoires may
explain the enhanced responses in HLA-DQ8 mice, as we noted that responsiveness to
concanavalin A (ConA) and medium alone was also greater in HLA-DQ8 mice. Notwith-
standing the in vitro ﬁndings, infection with a CC30 S. aureus isolate that produces a
high level of TSST-1 led to marked suppuration, abscess formation, and cytokine
production.
FIG 5 Antibiotics impact abscess volume, TSST-1 production, and mitogenicity during infection with TSST-1-producing S. aureus in
HLA-DQ8 mice. HLA-DQ8 mice were infected subcutaneously with tst-positive CC30 MSSA strain HSS357 (1  109 CFU). At 24 h, mice
received ﬂucloxacillin, clindamycin, ﬂucloxacillin and clindamycin, or 100 l PBS i.p. (as a control) and were culled at 30 h. (A) Abscess
dimensions were measured. (B) TSST-1 protein present in abscesses was measured by Western blotting. TSST-1 protein of known
concentration was also measured to quantify the amount of TSST-1 by densitometry. (C and D) Human PBMC responses to pus (C) and
serum (D) from infected mice were measured. Proliferation was measured by BrdU uptake. Negative, tissue culture medium (RPMI 1640)
alone. Medians and 5th, 25th, 50th, 75th, and 95th centiles are shown for ﬁve individual mice. *, P  0.05; **, P  0.01 by Mann-Whitney
U test comparing different antibiotic regimens with the control.
FIG 6 Interleukin-2 levels after antibiotic administration to HLA-DQ8 mice infected with TSST-1-
producing S. aureus. HLA-DQ8 mice were infected subcutaneously with tst-positive S. aureus strain
HSS357 (1  109 CFU). At 24 h, mice received ﬂucloxacillin, clindamycin, ﬂucloxacillin and clindamycin, or
100 l PBS i.p. (as a control) and were culled at 30 h. Serum was collected by cardiac puncture and
analyzed by immunoassay. Medians and 5th, 25th, 50th, 75th, and 95th centiles are shown for ﬁve
individual mice. *, P  0.05; **, P  0.01 by the Mann-Whitney U test compared to control mice injected
with PBS alone.
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We believe that the suppuration observed was in part related to TSST-1 responsive-
ness. It was not possible to evaluate an isogenic, tst-deﬁcient strain to determine which
of the observed effects were due solely to TSST-1; the CC30 lineage of S. aureus is
challenging to transform, although recent tools may now allow for its manipulation
(12). HSS357 carried (aside from tst) sei and seg, which are found in the enterotoxin
gene cluster (egc). The egc gene cluster is widespread in S. aureus strains (13) and
unlikely to have any speciﬁc association with TSS.
The measurement of TSST-1 production in vivo provides valuable contextual infor-
mation to inform future superantigen research. In some experiments, we detected
higher levels of TSST-1 in subcutaneous abscess pus than could be detected during
broth culture of the same strain (4) and higher levels than previously reported in the
abscesses and kidney extracts of mice infected with TSST-1-producing S. aureus (14, 15),
consistent with upregulation of superantigen production during suppurative infection.
Microbial spread and suppuration were noted in the ipsilateral inguinal lymph node, a
tissue rich in superantigen-sensitive T cells, and TSST-1 protein was detected here too
24 h after infection. The detection of bacteria and TSST-1 in ipsilateral, but not
contralateral, inguinal nodes is consistent with transit in afferent lymphatic vessels
rather than blood. During infection, abscessation was present in all the ipsilateral
FIG 7 Bacteriology of the antibiotic impact on HLA-DQ8 mice infected with TSST-1-producing S. aureus.
HLA-DQ8 mice were infected subcutaneously with tst-positive S. aureus strain HSS357 (1  109 CFU). At 24 h,
mice received ﬂucloxacillin, clindamycin, ﬂucloxacillin and clindamycin, or 100 l PBS i.p. (as a control) and were
culled at 30 h. (A) Abscess pus was extracted and plated for CFU counting; (B and C) ipsilateral/contralateral
inguinal lymph nodes (LN) were excised, homogenized, and plated for CFU counting; (D) spleens were
extracted, homogenized, and plated for CFU counting; (E) blood cultures were taken by cardiac puncture. Data
and medians are shown for 5 individual mice per group.
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inguinal lymph nodes, including those without detectable viable bacteria, as S. aureus
may have been killed by the neutrophils creating the pus. We cannot determine
whether TSST-1 was produced within the lymph node by S. aureus or transferred from
the site of infection via lymphatics. The proximity of TSST-1-producing S. aureus to such
lymphoid tissues may be pivotal to events occurring during TSS; the extent to which
this occurs in clinical disease is unknown. It is widely believed that TSS results from the
systemic dissemination of superantigens into the bloodstream and consequent inter-
action with leukocytes in the lympho-reticular system; in mice, the spleen is known to
act as a major source of cytokines following systemic superantigen administration (16).
Our results raise the possibility that superantigen exposure within secondary lymphoid
organs, such as the lymph nodes, may contribute to the cytokine storm underlying TSS
pathogenesis during infection. Previous studies using HLA transgenic mice have re-
ported IL-6, IFN-, and IL-2 serum responses in HLA-DQ8 mice exposed to aerosolized
SEB (17) and IL-6 and IFN- production by HLA-DR3 spleen cells exposed to SEB (18). We
detected cytokine responses to a bolus of toxin and to infection; IL-6, IFN-, KC, and
MCP-1 were the most consistent markers of inﬂammation.
Lethal shock was not observed or expected in this model; we note that sensitization
agents were not used and that bacterial clearance occurred over the 72-h experimental
period. Thus, this model does not replicate TSS as observed in humans but served to
elucidate potential pathways of TSST-1 production, dissemination, and abscess pro-
gression in a model that reproduces some of the immunological responses to staph-
ylococcal infection seen in humans. Previous models of TSS in HLA-DR1 mice required
D-galactosamine pretreatment to elicit liver failure, an event that is entirely related to
tumor necrosis factor (TNF)-induced hepatocyte apoptosis in the D-galactosamine
setting, while SEB alone results in cytokine release only (16). Changes in serum cytokine
levels were observed in both HLA-DQ6 and HLA-DQ8 mice at 4 h following SEB and
streptococcal pyrogenic exotoxin A (SPEA) challenge (19). In our study, weight loss, tst
transcripts, TSST-1 protein, and cytokines were maximal at 24 h following infection,
consistent with a marked systemic inﬂammatory response that might be like that
observed in nmTSS.
TSST-1 expanded TCR V subsets 3 and 13 in HLA-DQ8 mouse splenocytes. TSST-
1-induced TCR V15 and -17 subset expansion, as was previously reported in earlier
murine studies, could not be evaluated in the current study, as the assay used did not
detect them (20, 21). Further work to determine whether TSST-1 results in speciﬁc T-cell
V subset expansion and cytokine release within lymphoid organs in the context of S.
aureus infection would provide novel insight into nmTSS pathogenesis.
Notwithstanding ﬁndings in local lymph nodes, the mitogenicity assays strongly
pointed to the presence of superantigen in the sera of infected mice. While we could
not directly quantify TSST-1 in serum, parallel standard TSST-1 bioactivity assays yielded
data suggesting that 1 to 10 pg/ml of TSST-1 was present in the blood. TSST-1 at
0.2 pg/ml is reported to cause half-maximum proliferation of human T cells (2). We
cannot rule out the possibility that low levels of S. aureus were present in the blood
(limit of detection, 200 CFU/ml). However, the absence of a detectable bacteremia
supports the assertion that TSST-1 may disseminate from the initial infection site to
systemic circulation either by transcytosis across cellular barriers to reach the blood (22)
or via the lymphatic system, enabling activation of T cells distant to the site of infection.
Current TSS treatment recommendations advise a combination of -lactam and
lincosamide antibiotics, until culture results are known (5). This is based on in vitro
studies, extrapolation from observational studies of streptococcal TSS, and in vivo
evaluations of the effects of protein synthesis inhibitors in rabbit models of pneumonia
using Panton-Valentine leukocidin-producing S. aureus (23). There is a lack of published
in vivo data on the effect of clindamycin on TSST-1 production in any infection model.
We elected to evaluate this effect and whether using clindamycin at the outset of
TSS management might impact disease progression. We chose to treat a time point
when tst transcripts and TSST-1 protein were maximal and cytokines detectable.
Unsurprisingly, a single dose of antibiotic did not reduce abscess bacterial burden,
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consistent with previous ﬁndings (24). Notably, however, mice treated with clindamycin-
containing regimens had smaller abscesses, reduced TSST-1 production, and diminished
mitogenicity of pus and serum compared to those of mice treated with other regimens.
This is the ﬁrst work to demonstrate the superantigen-inhibitory effects of clindamycin
in vivo. The ﬁndings suggest that clindamycin may have an indirect effect on disease
and abscess progression, potentially by reducing TSST-1 synthesis, despite little mea-
surable effect on bacterial counts by this model. Previous reports do suggest that
abscessation may be enhanced by superantigens; hepatic abscesses are known to
develop in HLA transgenic mice exposed to SEA-producing S. aureus (25). Although
clindamycin can exert an inhibitory effect on superantigen-induced host cytokine
production in vitro (26), serum cytokine levels in our study did not demonstrate a
clear antibiotic effect, perhaps due to the timing of analysis following one antibiotic
dose.
Our ﬁndings support the adjunctive use of clindamycin to modify disease progres-
sion in the treatment of suspected staphylococcal TSS, to reduce superantigen toxin
production more rapidly, and to potentially reduce abscessation. Further studies are
required to increase our understanding of TSS pathogenesis and the role of lymph
node superantigen expression and to explore the efﬁcacy of treatment with other
immune modulators, such as intravenous immunoglobulin, to limit the lethal potential
of this syndrome.
MATERIALS AND METHODS
Animals. Female HLA class II transgenic mice on a C57BL/6 background carrying genomic constructs
for HLA-DQA1*0301/HLA-DQB*0302 (DQ8), HLA-DRA1*0101/HLA-DRB1*0401 (DR4, H2 A0; Taconic
Farms) (8, 27, 28), and C57BL/6 mice (Charles River, UK) that were 8 to 14 weeks old were used in
accordance with a UK Home Ofﬁce-approved project license following assessment by the Imperial
College Ethical Review Process. Mice were acclimatized for 1 week prior to use.
Bacterial culture. HSS357, a clinical tst-positive CC30 MSSA strain that caused TSS, was selected
based on highest in vitro TSST-1 production (187 ng/ml following overnight culture in 5 ml of brain heart
infusion [BHI] broth) among clinical tst-positive CC30 MSSA isolates causing TSS (4). Overnight culture of
strain HSS357 in 50 ml BHI yielded 400 ng/ml of TSST-1, although transcription of tst peaked at 8 h and
diminished thereafter (see Fig. S1 in the supplemental material). HSS357 was sensitive to all antibiotics,
including clindamycin and ﬂucloxacillin, with the exception of penicillin. Antibiotic MICs were deter-
mined by British Society for Antimicrobial Chemotherapy methods (http://www.bsac.org.uk) and inter-
preted in accordance with European Committee on Antimicrobial Susceptibility Testing guidelines
(http://www.eucast.org). HSS357 carried the superantigen genes seg and sei in addition to tst, deter-
mined by toxin gene proﬁling (sea to see, seg to sej, tst, and pvl) by multiplex PCR (29, 30).
For in vivo administration, HSS357 was cultured overnight in BHI broth at 37°C with agitation at
200 rpm and then centrifuged, washed, and resuspended in sterile phosphate-buffered saline (PBS).
Inocula, pus, and tissue samples for culture were plated onto Luria broth (LB) agar and incubated
overnight at 37°C prior to quantiﬁcation of CFU per milliliter.
Superantigen sensitivity in transgenic mice. Spleen cells (1  106/ml) from HLA-DQ8, HLA-DR4,
and C57BL/6 mice were prepared in RPMI 1640 medium (Invitrogen, Hemel Hempstead, UK) supple-
mented with 10% fetal calf serum, 2 mM glutamine, 50 U/ml penicillin and streptomycin, and 0.01 mM
mercaptoethanol and coincubated with 10 pg/ml to 10 g/ml of highly puriﬁed TSST-1, SEA, SEB, or SEC
(Toxin Technology, Sarasota, FL, USA) at 37°C for 48 h. Proliferation was measured after incorporation of
1.0 Ci/well of [3H]thymidine and an additional 16 h of incubation.
To assess TSST-1-induced T-cell receptor (TCR) V subset expansion, HLA-DQ8 spleen cells (1  106/
ml) were labeled with CellTrace far-red proliferation dye (CTFR; Thermo Fisher Scientiﬁc, Hemel Hemp-
stead, UK) and stimulated with 2.5 g/ml TSST-1 at 37°C for 72 h. Murine spleen cells were (i) blocked
with anti-mouse CD16/CD32, (ii) labeled with anti-CD3–phycoerythrin (PE) and anti-V–ﬂuorescein
isothiocyanate (FITC) (against either V subset 2, 3, 4, 5.1 and 5.2, 6, 7, 8.1 and 8.2, 8.3, 9, 10, 11, 12, 13,
or 14) (mouse V screening panel; BD Pharmingen), (iii) stained with 7-aminoactinomycin D (7-AAD)
viability dye, and (iv) acquired on a FACSCalibur ﬂow cytometer. Live CD3 V cells populations were
gated, and proliferation was determined by the intensity of CTFR staining using Flow Jo v10.1 (Tree Star)
and FCS Express v5 (De Novo Software).
To determine superantigen sensitivity in vivo, 80 g of TSST-1 in 100 l of PBS was administered
intraperitoneally to HLA-DQ8 and C57BL/6 mice. Blood was taken by tail bleed at 2 h and by cardiac
puncture at 6 h. Serum was separated and stored at –20°C for cytokine analysis.
Bacterial infection. HLA-DQ8 mice were infected subcutaneously on a shaved area of the right ﬂank
with 1  109 CFU of tst-positive S. aureus in 100 l sterile PBS or with PBS alone as a control. To
investigate antibiotic impact, mice were given intraperitoneal ﬂucloxacillin (FCX; 12.5 mg/kg of body
weight), clindamycin (CLD; 10 mg/kg), or ﬂucloxacillin with clindamycin (FCX-CLD, 12.5 mg/kg and
10 mg/kg, respectively) in 100 l of PBS or 100 l PBS as a control 24 h postinfection.
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Mice were euthanized at various time points postinfection, blood was taken by cardiac puncture for CFU
quantiﬁcation, and sera were collected and stored at –20°C for cytokine analysis and mitogenicity assays.
Abscess dimensions (height, width, and depth) were measured by a single observer using a mini-Vernier
caliper for all experiments. Pus was excised by forceps at the time of dissection and stored in sterile Tris-EDTA
buffer (10mM Tris-HCl, pH 8, 1mM EDTA). Aliquots of pus were taken for bacterial quantiﬁcation, storage at
–20°C for mitogenicity testing, RNA isolation (31), and local TSST-1 detection and quantiﬁcation by immu-
noblotting. Spleens and left and right inguinal lymph nodes were homogenized in sterile PBS for CFU
quantiﬁcation, and lymph nodes were stored at –20°C for ex vivo mitogenicity testing.
Expression of tst in vitro and in vivo. One microgram of cDNA was synthesized from bacterial RNA
treated with Turbo DNase (Ambion; Thermo Fisher) with Transcriptor reverse transcriptase (Roche, Basel,
Switzerland) and random hexamer primers (Sigma, Dorset, UK). Quantitative real-time PCR (qRT-PCR) was
performed using PCR primers for tst and the housekeeping gene rrsA (Table S1) with SYBR green
JumpStart Taq ReadyMix (Sigma). Transcript copies were calculated by comparison with standard 10-fold
concentrations of plasmid pCR2.1 (Invitrogen, Hemel Hempstead, UK) containing single copies of target
genes (tst or rrsA) ampliﬁed alongside bacterial cDNA. Numbers of copies of sample tst transcripts were
normalized to 10,000 copies of rrsA.
Detection of TSST-1 by Western blotting. Proteins were separated by 10% Bolt Bis-Tris Plus gel,
transferred to nitrocellulose (Amersham Protran, GE Healthcare, Amersham UK), blocked, and then
probed after incubation with rabbit anti-TSST-1 polyclonal antibody (Abcam, Cambridge, UK) and
anti-rabbit horseradish peroxidase (HRP)-conjugated antibody (Life Technologies, Hemel Hempstead, UK)
with an ECL Plus substrate detection system (Life Technologies). TSST-1 concentration in samples was
determined by comparison with standard concentrations of TSST-1 simultaneously analyzed by densi-
tometry (LabWorks, UVP, CA, USA). Samples below the detection limit were assigned half the value of the
lowest standard concentration detected.
Human T-cell proliferation assay. Normal donor peripheral blood mononuclear cells (PBMCs) from
anonymized consenting healthy donors were obtained from an approved subcollection of the Imperial
College NHS Trust Tissue Bank (ICHTB reference R12023). PBMCs (1  106/ml) were incubated in RPMI
1640 medium (Life Technologies) containing 10% fetal calf serum, 2 mM glutamine, and 50 U/ml of
penicillin and streptomycin with a 1:100 dilution of murine pus or mouse serum at 37°C for 48 h. All
measurements were performed as technical replicates in triplicate. T-cell proliferation was measured after
incorporation of 1.0 Ci/well of [3H]thymidine and an additional 16 h of incubation or after T cells were
labeled with 10 m of BrdU (Roche, Welwyn Garden City, UK) and incubated for a further 4 h. The BrdU
proliferation assay was used in place of [3H]thymidine incorporation during the study due to changes in
the use of radioisotopes within the laboratory.
Cytokine, chemokine, and growth factor measurement. Serum cytokines were measured on a
Bio-Rad Bio-Plex Luminex 200 system using a mouse 23-plex panel (Bio-Rad, CA, USA) that analyzed
eotaxin, G-CSF, granulocyte macrophage CSF (GM-CSF), IFN-, IL-1, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9,
IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17A, KC, MCP-1, MIP-1, MIP-1, RANTES, and TNF-. For analysis,
samples below the detection limit were assigned half the value of the lowest level detected.
Histopathology. Tissue was dissected from randomly selected single HLA-DQ8 mice at each infec-
tion time point and ﬁxed in formalin. Parafﬁn-embedded tissues were stained with hematoxylin and
eosin or Gram’s stain and reviewed in a blind manner by a histopathologist (M. El-Bahrawy).
Statistical analysis. Data are stated as medians (ranges) or means  standard deviations (SD). Data
were analyzed with GraphPad Prism 6.0 (GraphPad Software, CA, USA) using analysis of variance
(ANOVA), the Mann-Whitney U test, or an unpaired t test (two tailed) as indicated in the ﬁgure legends.
Probability values of 0.05 were considered signiﬁcant based on a two-tailed test.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00665-19.
FIG S1, TIF ﬁle, 0.1 MB.
FIG S2, TIF ﬁle, 0.3 MB.
FIG S3, TIF ﬁle, 0.1 MB.
FIG S4, TIF ﬁle, 1 MB.
TABLE S1, DOCX ﬁle, 0.02 MB.
TABLE S2, DOCX ﬁle, 0.03 MB.
TABLE S3, DOCX ﬁle, 0.03 MB.
ACKNOWLEDGMENTS
We acknowledge D. Kioussis and R. A. Flavell for transgenic mice and D. M. Altmann
for access, and we thank Nur S. C. Ahmad for technical contributions.
We acknowledge support from the NIHR Biomedical Research Centre (BRC) to the
Imperial College Healthcare Trust and the NIHR BRC-funded Tissue Bank. This work was
also supported by the UK Clinical Research Collaboration through a research training
fellowship (G0800777/1 to H.S.).
We have no conﬂicts of interest to declare.
TSST-1 in a Staphylococcal Soft Tissue Infection Model
September/October 2019 Volume 4 Issue 5 e00665-19 msphere.asm.org 11
REFERENCES
1. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. 1990. Staphylococcal and
streptococcal pyrogenic toxins involved in toxic shock syndrome and
related illnesses. Crit Rev Microbiol 17:251–272. https://doi.org/10.3109/
10408419009105728.
2. Fraser JD, Proft T. 2008. The bacterial superantigen and superantigen-
like proteins. Immunol Rev 225:226–243. https://doi.org/10.1111/j.1600
-065X.2008.00681.x.
3. Whiting JL, Rosten PM, Chow AW. 1989. Determination by Western blot
(immunoblot) of seroconversions to toxic shock syndrome (TSS) toxin 1
and enterotoxin A, B, or C during infection with TSS- and non-TSS-
associated Staphylococcus aureus. Infect Immun 57:231–234.
4. Sharma H, Smith D, Turner CE, Game L, Pichon B, Hope R, Hill R, Kearns
A, Sriskandan S. 2018. Clinical and molecular epidemiology of staphylo-
coccal toxic shock syndrome in the United Kingdom. Emerg Infect Dis
24:258–266. https://doi.org/10.3201/eid2402.170606.
5. American Academy of Pediatrics. 2015. Staphylococcal infections, p
715–732. In Kimberlin DW, Brady MT, Jackson MA, Long SS (ed), Red
book: 2015 report of the Committee on Infectious Diseases. American
Academy of Pediatrics, Elk Grove Village, IL.
6. Dinges MM, Schlievert PM. 2001. Comparative analysis of
lipopolysaccharide-induced tumor necrosis factor alpha activity in serum
and lethality in mice and rabbits pretreated with the staphylococcal
superantigen toxic shock syndrome toxin 1. Infect Immun 69:
7169–7172. https://doi.org/10.1128/IAI.69.11.7169-7172.2001.
7. Faulkner L, Altmann DM, Ellmerich S, Huhtaniemi I, Stamp G, Sriskandan
S. 2007. Sexual dimorphism in superantigen shock involves elevated
TNF-alpha and TNF-alpha induced hepatic apoptosis. Am J Respir Crit
Care Med 176:473–482. https://doi.org/10.1164/rccm.200611-1712OC.
8. Sriskandan S, Unnikrishnan M, Krausz T, Dewchand H, Van Noorden S,
Cohen J, Altmann DM. 2001. Enhanced susceptibility to superantigen-
associated streptococcal sepsis in human leukocyte antigen-DQ trans-
genic mice. J Infect Dis 184:166–173. https://doi.org/10.1086/322018.
9. Herrmann T, Accolla RS, MacDonald HR. 1989. Different staphylococcal
enterotoxins bind preferentially to distinct major histocompatibility
complex class II isotypes. Eur J Immunol 19:2171–2174. https://doi.org/
10.1002/eji.1830191131.
10. Uchiyama T, Saito S, Inoko H, Yan XJ, Imanishi K, Araake M, Igarashi H.
1990. Relative activities of distinct isotypes of murine and human major
histocompatibility complex class II molecules in binding toxic shock
syndrome toxin 1 and determination of CD antigens expressed on T cells
generated upon stimulation by the toxin. Infect Immun 58:3877–3882.
11. Krogman A, Tilahun A, David CS, Chowdhary VR, Alexander MP, Rajago-
palan G. 2016. HLA-DR polymorphisms inﬂuence in vivo responses to
staphylococcal toxic shock syndrome toxin-1 in a transgenic mouse
model. HLA 89:20–28. https://doi.org/10.1111/tan.12930.
12. Monk IR, Shah IM, Xu M, Tan MW, Foster TJ. 2012. Transforming the
untransformable: application of direct transformation to manipulate
genetically Staphylococcus aureus and Staphylococcus epidermidis.
mBio 3:e00277-11. https://doi.org/10.1128/mBio.00277-11.
13. Grumann D, Nubel U, Broker BM. 2014. Staphylococcus aureus toxins—
their functions and genetics. Infect Genet Evol 21:583–592. https://doi
.org/10.1016/j.meegid.2013.03.013.
14. Quimby F, Nguyen HT. 1985. Animal studies of toxic shock syndrome. Crit
Rev Microbiol 12:1–44. https://doi.org/10.3109/10408418509104424.
15. Lee JC, Perez NE, Hopkins CA. 1989. Production of toxic shock syndrome
toxin 1 in a mouse model of Staphylococcus aureus abscess formation.
Rev Infect Dis 11(Suppl 1):S254–S259. https://doi.org/10.1093/clinids/11
.Supplement_1.S254.
16. Faulkner L, Cooper A, Fantino C, Altmann DM, Sriskandan S. 2005. The
mechanism of superantigen-mediated toxic shock: not a simple Th1
cytokine storm. J Immunol 175:6870–6877. https://doi.org/10.4049/
jimmunol.175.10.6870.
17. Roy CJ, Warﬁeld KL, Welcher BC, Gonzales RF, Larsen T, Hanson J, David
CS, Krakauer T, Bavari S. 2005. Human leukocyte antigen-DQ8 transgenic
mice: a model to examine the toxicity of aerosolized staphylococcal
enterotoxin B. Infect Immun 73:2452–2460. https://doi.org/10.1128/IAI
.73.4.2452-2460.2005.
18. DaSilva L, Welcher BC, Ulrich RG, Aman MJ, David CS, Bavari S. 2002.
Humanlike immune response of human leukocyte antigen-DR3 trans-
genic mice to staphylococcal enterotoxins: a novel model for superan-
tigen vaccines. J Infect Dis 185:1754–1760. https://doi.org/10.1086/
340828.
19. Rajagopalan G, Polich G, Sen MM, Singh M, Epstein BE, Lytle AK, Rouse
MS, Patel R, David CS. 2008. Evaluating the role of HLA-DQ polymor-
phisms on immune response to bacterial superantigens using transgenic
mice. Tissue Antigens 71:135–145. https://doi.org/10.1111/j.1399-0039
.2007.00986.x.
20. Marrack P, Kappler J. 1990. The staphylococcal enterotoxins and their
relatives. Science 248:1066. https://doi.org/10.1126/science.248.4959
.1066-b.
21. Callahan JE, Herman A, Kappler JW, Marrack P 1990. Stimulation of
B10.BR T cells with superantigenic staphylococcal toxins. J Immunol
144:2473–2479.
22. Hamad AR, Marrack P, Kappler JW. 1997. Transcytosis of staphylococcal
superantigen toxins. J Exp Med 185:1447–1454. https://doi.org/10.1084/
jem.185.8.1447.
23. Croisier-Bertin D, Hayez D, Da Silva S, Labrousse D, Biek D, Badiou C,
Dumitrescu O, Guerard P, Charles PE, Piroth L, Lina G, Vandenesch F,
Chavanet P 2014. In vivo efﬁcacy of ceftaroline fosamil in a methicillin-
resistant Panton-Valentine leukocidin-producing Staphylococcus aureus
rabbit pneumonia model. Antimicrob Agents Chemother 58:1855–1861.
https://doi.org/10.1128/AAC.01707-13.
24. Turner CE, Sriskandan S. 2015. Panton-Valentine leucocidin expression
by Staphylococcus aureus exposed to common antibiotics. J Infect
71:338–346. https://doi.org/10.1016/j.jinf.2015.05.008.
25. Xu SX, Gilmore KJ, Szabo PA, Zeppa JJ, Baroja ML, Haeryfar SM, Mc-
Cormick JK. 2014. Superantigens subvert the neutrophil response to pro-
mote abscess formation and enhance Staphylococcus aureus survival in
vivo. Infect Immun 82:3588–3598. https://doi.org/10.1128/IAI.02110-14.
26. Pichereau S, Moran JJ, Hayney MS, Shukla SK, Sakoulas G, Rose WE. 2012.
Concentration-dependent effects of antimicrobials on Staphylococcus
aureus toxin-mediated cytokine production from peripheral blood
mononuclear cells. J Antimicrob Chemother 67:123–129. https://doi.org/
10.1093/jac/dkr417.
27. Ito K, Bian HJ, Molina M, Han J, Magram J, Saar E, Belunis C, Bolin DR,
Arceo R, Campbell R, Falcioni F, Vidovic D, Hammer J, Nagy ZA. 1996.
HLA-DR4-IE chimeric class II transgenic, murine class II-deﬁcient mice are
susceptible to experimental allergic encephalomyelitis. J Exp Med 183:
2635–2644. https://doi.org/10.1084/jem.183.6.2635.
28. Wen L, Wong FS, Burkly L, Altieri M, Mamalaki C, Kioussis D, Flavell RA,
Sherwin RS. 1998. Induction of insulitis by glutamic acid decarboxylase
peptide-speciﬁc and HLA-DQ8-restricted CD4() T cells from human DQ
transgenic mice. J Clin Invest 102:947–957. https://doi.org/10.1172/
JCI2723.
29. Milheirico C, Oliveira DC, de Lencastre H. 2007. Update to the multiplex
PCR strategy for assignment of mec element types in Staphylococcus
aureus. Antimicrob Agents Chemother 51:3374–3377. https://doi.org/10
.1128/AAC.00275-07.
30. Boakes E, Kearns AM, Ganner M, Perry C, Warner M, Hill RL, Ellington MJ.
2011. Molecular diversity within clonal complex 22 methicillin-resistant
Staphylococcus aureus encoding Panton-Valentine leukocidin in Eng-
land and Wales. Clin Microbiol Infect 17:140–145. https://doi.org/10
.1111/j.1469-0691.2010.03199.x.
31. Turner CE, Kurupati P, Jones MD, Edwards RJ, Sriskandan S. 2009. Emerg-
ing role of the interleukin-8 cleaving enzyme SpyCEP in clinical Strep-
tococcus pyogenes infection. J Infect Dis 200:555–563. https://doi.org/
10.1086/603541.
Sharma et al.
September/October 2019 Volume 4 Issue 5 e00665-19 msphere.asm.org 12
